Verzenio showed promising efficacy in high-grade meningiomas with CDK pathway or NF2 alterations, achieving progression-free survival at six months in 14 of 24 patients. Patients with NF2 alterations ...

The anti–programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)–positive advanced solid tumors.

Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a ...

Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that ...

After a decade of experience a reappraisal of the effects of steroids on the L.E. cell and of the relation of disease activity to the presence of L.E. cells seems indicated. The availability of ...